Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
Total Valuation
GlaxoSmithKline has a market cap or net worth of $123.00B. The enterprise value is $103.60B.
Market Cap$123.00B
Enterprise Value$103.60B
Share Statistics
GlaxoSmithKline has 2,037,915,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,037,915,800
Owned by Insiders―
Owned by Institutions0.45%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.34 and return on invested capital (ROIC) is 13.97%.
Return on Equity (ROE)0.34
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)13.97%
Return on Capital Employed (ROCE)0.18
Revenue Per Employee465.56K
Profits Per Employee81.46K
Employee Count68,629
Asset Turnover0.52
Inventory Turnover1.48
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 16.4. GlaxoSmithKline’s PEG ratio is 0.11.
PE Ratio16.4
PS Ratio2.31
PB Ratio4.51
Price to Fair Value4.51
Price to FCF12.66
Price to Operating Cash Flow11.78
PEG Ratio0.11
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 31.95B and earned 5.59B in profits. Earnings per share was 2.76.
Revenue31.95B
Gross Profit23.18B
Operating Income7.01B
Pretax Income7.24B
Net Income5.59B
EBITDA11.62B
Earnings Per Share (EPS)2.76
Cash Flow
In the last 12 months, operating cash flow was 8.30B and capital expenditures -2.07B, giving a free cash flow of 6.24B billion.
Operating Cash Flow8.30B
Free Cash Flow6.24B
Free Cash Flow per Share3.06
Dividends & Yields
GlaxoSmithKline pays an annual dividend of $0.41, resulting in a dividend yield of 3.41%
Dividend Per Share$0.41
Dividend Yield3.41%
Payout Ratio37.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change66.91%
50-Day Moving Average51.49
200-Day Moving Average43.18
Relative Strength Index (RSI)70.79
Average Volume (3m)5.94M
Important Dates
GlaxoSmithKline upcoming earnings date is Apr 29, 2026, Before Open (Confirmed).
Last Earnings DateFeb 4, 2026
Next Earnings DateApr 29, 2026
Ex-Dividend Date―
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 108.20%
Current Ratio0.82
Quick Ratio0.54
Debt to Market Cap0.24
Net Debt to EBITDA1.23
Interest Coverage Ratio10.23
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.09B in taxes.
Income Tax1.09B
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 7.57, with an EV/FCF ratio of 15.11.
EV to Sales2.75
EV to EBITDA7.57
EV to Free Cash Flow15.11
EV to Operating Cash Flow12.32
Balance Sheet
GlaxoSmithKline has $3.40B in cash and marketable securities with $17.69B in debt, giving a net cash position of -$14.29B billion.
Cash & Marketable Securities$3.40B
Total Debt$17.69B
Net Cash-$14.29B
Net Cash Per Share-$7.01
Tangible Book Value Per Share-$3.82
Margins
Gross margin is 72.49%, with operating margin of 21.95%, and net profit margin of 17.50%.
Gross Margin72.49%
Operating Margin21.95%
Pretax Margin22.66%
Net Profit Margin17.50%
EBITDA Margin36.38%
EBIT Margin24.81%
Analyst Forecast
The average price target for GlaxoSmithKline is $47.22, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$47.22
Price Target Upside-20.67% Downside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast5.97%
EPS Growth Forecast128.66%